2020
DOI: 10.3389/fonc.2020.00126
|View full text |Cite
|
Sign up to set email alerts
|

Antiangiogeneic Strategies in Mesothelioma

Abstract: There is a strong rationale for inhibiting angiogenesis in mesothelioma. Vascular endothelial growth factor (VEGF) is an autocrine growth factor in mesothelioma and a potent mitogen for mesothelial cells. Further, the abnormal tumor vasculature promotes raised interstitial pressure and hypoxia, which may be detrimental to both penetration and efficacy of anticancer agents. Antiangiogenic agents have been trialed in mesothelioma for close to two decades, with early phase clinical trials testing vascular targeti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
27
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 32 publications
(29 citation statements)
references
References 94 publications
2
27
0
Order By: Relevance
“…Antiangiogenic therapeutic approaches have been widely investigated as reviewed recently by Novak et al [150]. Thus, the clinical use of the VEGF inhibitor bevacizumab is now also regarded as promising improvement of the almost 20 year old standard chemotherapy regimen published by Vogelzang et al [151] according to the promising results of the MAPS trial [152].…”
Section: Interleukinmentioning
confidence: 99%
“…Antiangiogenic therapeutic approaches have been widely investigated as reviewed recently by Novak et al [150]. Thus, the clinical use of the VEGF inhibitor bevacizumab is now also regarded as promising improvement of the almost 20 year old standard chemotherapy regimen published by Vogelzang et al [151] according to the promising results of the MAPS trial [152].…”
Section: Interleukinmentioning
confidence: 99%
“…Likewise, deregulated angiogenesis is an integral component of the highly aggressive behavior, and the chemotherapy-resistant nature of MPM [ 102 , 103 ]. This has been obtrusive by way of augmented expression of HIF-1α (hypoxia-inducible factor 1α) and elevated blood neovascularization as measured via vessel density [ 104 , 105 ]. Furthermore, deregulations in master regulators of angiogenesis, which include increased expression of VEGF (vascular endothelial growth factor) family proteins and their specific receptors (VEGFRs), and the downstream targets of VEGF/VEGFR signaling axis, mainly the RTK signaling mediators PKC (protein kinase C) and Akt, have been implicated in MPM tumorigenesis [ 106 ].…”
Section: Genomics Of Malignant Pleural Mesotheliomamentioning
confidence: 99%
“…Similarly, deregulation of FGF and PDGF pathways by virtue of autocrine and paracrine signaling, have been associated with MPM cell survival and angiogenesis [ 107 ]. Despite the negative results with earlier antiangiogenic therapies, newly designed clinical studies targeting VEGF and other growth factor signaling pathways, alone or in combination, are underway [ 105 ].…”
Section: Genomics Of Malignant Pleural Mesotheliomamentioning
confidence: 99%
“…Recently, the addition of an anti- vascular endothelial growth factor (anti-VEGF) therapy (Bevacizumab) has been shown to enhance OS when given in the first line setting [ 13 ]. And whilst this therapeutic combination is now the new standard of care in France [ 14 ], it has not yet been approved by the FDA, issues with cost and lack of reimbursement prevent it from being added to the SOC in many countries, and other anti-angiogenic combinations have not been successful [ 15 ].…”
Section: Introductionmentioning
confidence: 99%